Monte Rosa Therapeutics vs Recursion Pharmaceuticals
GLUE and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GLUE and RXRX compare
Recursion Pharmaceuticals is the larger company, worth 2.1 times as much as Monte Rosa Therapeutics ($1.7B against $799M).
Recursion Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus −61.3% for Monte Rosa Therapeutics).
Monte Rosa Therapeutics keeps more of each dollar of sales as profit, with a net margin of −186% compared with −697% at Recursion Pharmaceuticals.
Recursion Pharmaceuticals scores higher on the StockData Score (8 against 7 for Monte Rosa Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GLUE | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | $799M | $1.7B |
| Share price | $9.37 | $3.19 |
| Change, 1 year | −33.8% | −31.5% |
| Change, 5 years | −52.1% | −83.9% |
| Beta (5Y) | 1.83 | 2.65 |
| Employees | 150 | 50 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.4× (better) | 25.0× |
| P/B | 1.6× (better) | 1.9× |
| FCF yield | −21.8% | −18.3% (better) |
| Fair value | $8.37 | $3.14 |
| Margin of safety | −11.9% | −1.5% (better) |
| Growth | ||
| Revenue growth (TTM) | −61.3% | 56.2% (better) |
| Revenue growth, 5Y average | – | 79.9% |
| Net income growth (TTM) | −725% | – |
| EPS growth (TTM) | −660% | – |
| Profitability | ||
| Gross margin | – | 29.2% |
| Operating margin | −214% (better) | −725% |
| Net margin | −186% (better) | −697% |
| FCF margin | −248% (better) | −458% |
| Return on equity | −35.3% (better) | −48.7% |
| Return on invested capital | – | −102% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Interest coverage | – | −541.6× |
| Current ratio | 10.32 (better) | 5.01 |
| Altman Z-score | 1.63 (better) | −0.36 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.8% |
| Shareholder yield | 0.00% (better) | −12.8% |
| Ownership | ||
| Held by institutions | 109% | 67.6% |
| Held by insiders | 11.5% | 5.6% |
| Insider net buying, 12 months | −$4.1M (better) | −$7.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 27.6% | 28.2% |
Go deeper
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.